Visceral Prolapse
Conditions
Keywords
pelvic organ prolapse, POP, vault prolapse, cystocele, vaginal prolapse, post-hysterectomy vaginal prolapse
Brief summary
The study is a multi-center, randomized, surgical trial of women with symptomatic post-hysterectomy apical (cuff) prolapse desiring surgical treatment. This study will compare the three available surgical treatments performed in usual practice. The purpose of this study is to compare two commonly performed mesh apical repair (sacral colpopexy vs. Apical Transvaginal Mesh) and vaginal native tissue apical repairs with mesh reinforced repairs. The primary outcome is measured over time (up to 60 months) using a survival analysis approach. Participants will be followed for at least 36-months (3-years) post surgery and up to a maximum of 60-months (5-years) during the primary trial. Participants who complete the primary trial will be approached for consent for long-term follow-up as part of a study extension and will be followed up to a maximum of 120-months (10-years). The investigators hypothesize that treatment failure will not differ between vaginally and abdominally placed mesh for vault vaginal prolapse, and mesh repairs (regardless of route of implantation) will be superior to native tissue apical suspension.
Detailed description
The primary purpose of this three arm randomized clinical trial is to determine if apical transvaginal mesh placement is non-inferior to sacral colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse and to determine if mesh reinforced repairs performed by abdominal or vaginal approach are superior to native tissue vaginal repair. This trial has the following primary aims: 1\. To determine if Apical Transvaginal Mesh is non-inferior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 1A. In the case where Apical Transvaginal Mesh is shown to be statistically significantly non-inferior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years, to determine if Apical Transvaginal Mesh is superior to Sacral Colpopexy for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 2\. To determine if Sacral Colpopexy is superior to Native Tissue Repair for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. 3\. To determine if Apical Transvaginal Mesh is superior to Native Tissue Repair for anatomic correction of post-hysterectomy vaginal vault prolapse at time points through 3 years. Additional secondary aims include: 1. Evaluate the development of a valid and reliable Global Composite Outcome that balances adverse events and patient-centered outcomes to anatomic definitions of failure and success. 2. Determine the impact of preoperative frailty and mobility on surgical treatment outcomes and postoperative complications of older women following surgical correction of apical pelvic organ prolapse. 3. Evaluate the patient's perspective about adverse events and their role in patient decision-making outcomes. The aims include comparing patient versus surgeon rankings of complication grade, outcome, expectedness and seriousness, to estimate the association between patient rankings of adverse events (AEs) with decision-making and quality of life outcomes and to determine if their perspective about AEs changes over time.
Interventions
Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Women age 21 or older 2. Prior total hysterectomy (no cervix present) 3. Prolapse beyond the hymen (defined as Ba, C, or Bp \> 0 cm) 4. Vaginal cuff descent into at least the lower two thirds of the vagina (defined as point C\> -2/3 TVL) 5. Bothersome bulge symptoms as indicated on question 3 of the PFDI-20 form relating to 'sensation of bulging' or 'something falling out' 6. Desires surgical treatment for post-hysterectomy vaginal prolapse 7. Available for up to 60 month follow-up
Exclusion criteria
1. Previous synthetic material or biologic grafts (placed vaginally or abdominally) to augment POP repair including anterior, posterior and/or apical compartments 2. Known previous formal SSLS performed for either uterovaginal or post-hysterectomy vaginal vault prolapse \* 3. Known adverse reaction to synthetic mesh or biological grafts; these complications include but are not limited to erosion, fistula, or abscess 4. Unresolved chronic pelvic pain-active 5. Prior abdominal or pelvic radiation 6. Contraindication to any of the index surgical procedures * Known Horseshoe Kidney or Pelvic Mass overlying the sacrum * Active diverticular abscess or active diverticulitis * Shortened vaginal length (\<6 cm TVL) * NOTE: * Only documented SSLS will be an exclusion. * Mesh used for only mid-urethral sling will NOT be an exclusion * If prior POP repair is unknown and unable to be documented, subjects will be eligible based on clinician judgment. The investigator will examine and assess for evidence of mesh or graft if no evidence of mesh or graft is present on examination subject remains eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Considered Failures | 6 months through 60 Months | Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit. |
Countries
United States
Contacts
Kaiser Permanente San Diego
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Native Tissue Transvaginal Native Tissue Repair: Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable | 123 |
| Sacral Colpopexy Open, Robotic, or Laparoscopic: Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or | 121 |
| Transvaginal Mesh Uphold� LITE: Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached t | 116 |
| Total | 360 |
Baseline characteristics
| Characteristic | Native Tissue | Total | Transvaginal Mesh | Sacral Colpopexy |
|---|---|---|---|---|
| Age, Continuous | 66.4 years STANDARD_DEVIATION 8.5 | 66.1 years STANDARD_DEVIATION 8.7 | 66.4 years STANDARD_DEVIATION 9 | 65.4 years STANDARD_DEVIATION 8.6 |
| Body Mass Index | 27.9 kg/m^2 STANDARD_DEVIATION 5.5 | 28.7 kg/m^2 STANDARD_DEVIATION 5.8 | 28.7 kg/m^2 STANDARD_DEVIATION 5.1 | 29.5 kg/m^2 STANDARD_DEVIATION 6.4 |
| Current Smoker No | 90 Participants | 260 Participants | 78 Participants | 92 Participants |
| Current Smoker Unknown | 25 Participants | 74 Participants | 27 Participants | 22 Participants |
| Current Smoker Yes | 8 Participants | 26 Participants | 11 Participants | 7 Participants |
| Education 4-Year College Degree | 24 Participants | 70 Participants | 23 Participants | 23 Participants |
| Education Associate College Degree | 28 Participants | 97 Participants | 35 Participants | 34 Participants |
| Education Graduate Degree | 11 Participants | 28 Participants | 5 Participants | 12 Participants |
| Education High School/GED | 47 Participants | 126 Participants | 40 Participants | 39 Participants |
| Education Less than High School | 10 Participants | 30 Participants | 11 Participants | 9 Participants |
| Education Unknown/ Not Reported | 3 Participants | 9 Participants | 2 Participants | 4 Participants |
| Marital Status Divorced/ Separated | 26 Participants | 59 Participants | 12 Participants | 21 Participants |
| Marital Status MARRIED, HUSBAND IN LOUISIANA | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Marital Status Married /Living with partner | 82 Participants | 244 Participants | 85 Participants | 77 Participants |
| Marital Status Single (never been married) | 7 Participants | 19 Participants | 4 Participants | 8 Participants |
| Marital Status Widowed | 8 Participants | 37 Participants | 15 Participants | 14 Participants |
| Pregnancies | 3 Number of pregnancies | 3 Number of pregnancies | 3 Number of pregnancies | 3 Number of pregnancies |
| Race/Ethnicity, Customized American Indian/Alaskan Native | 5 Participants | 6 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 1 Participants | 3 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Black/African American | 10 Participants | 35 Participants | 12 Participants | 13 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 21 Participants | 48 Participants | 12 Participants | 15 Participants |
| Race/Ethnicity, Customized More than one race | 2 Participants | 3 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 98 Participants | 305 Participants | 104 Participants | 103 Participants |
| Race/Ethnicity, Customized Other | 4 Participants | 11 Participants | 3 Participants | 4 Participants |
| Race/Ethnicity, Customized Unknown/ Not Reported | 4 Participants | 7 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 101 Participants | 302 Participants | 99 Participants | 102 Participants |
| Sex/Gender, Customized Female | 123 Participants | 360 Participants | 116 Participants | 121 Participants |
| Vaginal Deliveries | 3 Number of deliveries | 2 Number of deliveries | 2.5 Number of deliveries | 2 Number of deliveries |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 123 | 1 / 121 | 5 / 116 |
| other Total, other adverse events | 100 / 123 | 88 / 121 | 91 / 116 |
| serious Total, serious adverse events | 14 / 123 | 24 / 121 | 25 / 116 |
Outcome results
Number of Participants Considered Failures
Failure was defined as any of the following: retreatment for prolapse, any POP-Q measure beyond the hymen, or presence of bother on PFDI vaginal bulge question. Under the permanent failure state assumption, the number of participants shown at each visit includes all participants who were still participating in the study or had a failure outcome prior their withdrawal. Similarly, the denominator number of participants for the cumulative failure at each visit includes all participants who were still participating in the study and attended the visit or had any failure outcome prior their withdrawal or missed visit.
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Native Tissue | Number of Participants Considered Failures | 24 Months | Non-failure | 62 Participants |
| Native Tissue | Number of Participants Considered Failures | 12 Months | Failure | 31 Participants |
| Native Tissue | Number of Participants Considered Failures | 12 Months | Non-failure | 81 Participants |
| Native Tissue | Number of Participants Considered Failures | 18 Months | Failure | 38 Participants |
| Native Tissue | Number of Participants Considered Failures | 18 Months | Non-failure | 68 Participants |
| Native Tissue | Number of Participants Considered Failures | 24 Months | Failure | 43 Participants |
| Native Tissue | Number of Participants Considered Failures | 30 Months | Non-failure | 53 Participants |
| Native Tissue | Number of Participants Considered Failures | 36 Months | Failure | 53 Participants |
| Native Tissue | Number of Participants Considered Failures | 36 Months | Non-failure | 53 Participants |
| Native Tissue | Number of Participants Considered Failures | 42 Months | Failure | 55 Participants |
| Native Tissue | Number of Participants Considered Failures | 42 Months | Non-failure | 40 Participants |
| Native Tissue | Number of Participants Considered Failures | 48 Months | Failure | 55 Participants |
| Native Tissue | Number of Participants Considered Failures | 54 Months | Failure | 55 Participants |
| Native Tissue | Number of Participants Considered Failures | 54 Months | Non-failure | 29 Participants |
| Native Tissue | Number of Participants Considered Failures | 60 Months | Failure | 55 Participants |
| Native Tissue | Number of Participants Considered Failures | 60 Months | Non-failure | 21 Participants |
| Native Tissue | Number of Participants Considered Failures | 06 Months | Failure | 19 Participants |
| Native Tissue | Number of Participants Considered Failures | 06 Months | Non-failure | 93 Participants |
| Native Tissue | Number of Participants Considered Failures | 30 Months | Failure | 49 Participants |
| Native Tissue | Number of Participants Considered Failures | 48 Months | Non-failure | 38 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 36 Months | Failure | 31 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 06 Months | Non-failure | 108 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 36 Months | Non-failure | 69 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 24 Months | Failure | 21 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 42 Months | Non-failure | 57 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 48 Months | Non-failure | 50 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 54 Months | Failure | 36 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 30 Months | Failure | 24 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 54 Months | Non-failure | 30 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 60 Months | Failure | 38 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 12 Months | Failure | 13 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 60 Months | Non-failure | 25 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 12 Months | Non-failure | 96 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 18 Months | Failure | 18 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 42 Months | Failure | 33 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 18 Months | Non-failure | 86 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 06 Months | Failure | 6 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 24 Months | Non-failure | 83 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 30 Months | Non-failure | 75 Participants |
| Sacral Colpopexy | Number of Participants Considered Failures | 48 Months | Failure | 36 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 60 Months | Failure | 37 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 36 Months | Failure | 30 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 36 Months | Non-failure | 70 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 06 Months | Non-failure | 100 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 18 Months | Non-failure | 84 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 42 Months | Failure | 31 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 12 Months | Failure | 18 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 30 Months | Non-failure | 75 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 42 Months | Non-failure | 62 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 24 Months | Non-failure | 80 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 06 Months | Failure | 11 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 48 Months | Non-failure | 53 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 48 Months | Failure | 31 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 12 Months | Non-failure | 89 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 54 Months | Failure | 35 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 60 Months | Non-failure | 23 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 24 Months | Failure | 27 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 54 Months | Non-failure | 39 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 30 Months | Failure | 30 Participants |
| Transvaginal Mesh | Number of Participants Considered Failures | 18 Months | Failure | 19 Participants |
Change From Baseline Body Part Pain Scale
The Body Part Pain Scale measuring the pain experienced in the lower abdomen and pelvic region of the body is composed of 7 questions, each with a yes (1) or no (0) questions about experiencing pain followed by an intensity rating: 0 (No pain),..., 10 (Most intense). The score is calculated as the average of the responses. The range of responses is: 0-10 with 0 (No pain) to 10 (most intense pain). Lower scores indicate better function / fewer symptoms. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Body Part Pain Scale | 60 Months | -0.3 units on a scale |
| Native Tissue | Change From Baseline Body Part Pain Scale | 36 Months | -0.3 units on a scale |
| Native Tissue | Change From Baseline Body Part Pain Scale | 06 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Body Part Pain Scale | 24 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Body Part Pain Scale | 12 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Body Part Pain Scale | 48 Months | -0.2 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 60 Months | -0.7 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 12 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 06 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 24 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 48 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Body Part Pain Scale | 36 Months | -0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 48 Months | -0.5 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 06 Months | -0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 12 Months | -0.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 36 Months | -0.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 60 Months | -0.2 units on a scale |
| Transvaginal Mesh | Change From Baseline Body Part Pain Scale | 24 Months | -0.7 units on a scale |
Change From Baseline CRADI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline CRADI Score | 06 Months | -12.3 units on a scale |
| Native Tissue | Change From Baseline CRADI Score | 36 Months | -11.9 units on a scale |
| Native Tissue | Change From Baseline CRADI Score | 12 Months | -12.9 units on a scale |
| Native Tissue | Change From Baseline CRADI Score | 48 Months | -12.3 units on a scale |
| Native Tissue | Change From Baseline CRADI Score | 24 Months | -12.8 units on a scale |
| Native Tissue | Change From Baseline CRADI Score | 60 Months | -7.8 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 06 Months | -13.1 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 24 Months | -14.8 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 36 Months | -14.3 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 48 Months | -12.2 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 60 Months | -10.5 units on a scale |
| Sacral Colpopexy | Change From Baseline CRADI Score | 12 Months | -14.6 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 60 Months | -13.1 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 24 Months | -14 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 06 Months | -14.2 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 36 Months | -13.5 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 12 Months | -14.2 units on a scale |
| Transvaginal Mesh | Change From Baseline CRADI Score | 48 Months | -12.7 units on a scale |
Change From Baseline CRAIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline CRAIQ Score | 06 Months | -10.1 units on a scale |
| Native Tissue | Change From Baseline CRAIQ Score | 12 Months | -10.2 units on a scale |
| Native Tissue | Change From Baseline CRAIQ Score | 24 Months | -7.1 units on a scale |
| Native Tissue | Change From Baseline CRAIQ Score | 48 Months | -5.2 units on a scale |
| Native Tissue | Change From Baseline CRAIQ Score | 36 Months | -7.6 units on a scale |
| Native Tissue | Change From Baseline CRAIQ Score | 60 Months | -3.8 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 60 Months | -6.8 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 06 Months | -9.1 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 12 Months | -9.4 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 36 Months | -9.4 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 24 Months | -9.8 units on a scale |
| Sacral Colpopexy | Change From Baseline CRAIQ Score | 48 Months | -9.3 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 36 Months | -6.3 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 60 Months | -2.4 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 06 Months | -9.2 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 12 Months | -9.7 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 24 Months | -9.2 units on a scale |
| Transvaginal Mesh | Change From Baseline CRAIQ Score | 48 Months | -4.3 units on a scale |
Change From Baseline Functional Activity Scale
Functional Activity Scale measuring the impact of incontinence symptoms on a woman's daily activities is composed of 13 questions about normal and physically strenuous daily activities. The range of responses on the individual questions is (1) No difficulty,... (5) Not able to do it. Scores are calculated by subtracting from the maximum sum (5\*13=65) the product of the mean response and number of questions, then dividing by the total range of sums (65 - 13 = 52) and multiplying by 100. The range of responses is: 0-100 with 0 (worse functionality) to 100 (Better functionality). Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Functional Activity Scale | 60 Months | -0.8 units on a scale |
| Native Tissue | Change From Baseline Functional Activity Scale | 12 Months | 4.6 units on a scale |
| Native Tissue | Change From Baseline Functional Activity Scale | 48 Months | 2.4 units on a scale |
| Native Tissue | Change From Baseline Functional Activity Scale | 24 Months | 3.5 units on a scale |
| Native Tissue | Change From Baseline Functional Activity Scale | 36 Months | 2.6 units on a scale |
| Native Tissue | Change From Baseline Functional Activity Scale | 06 Months | 3.9 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 36 Months | 7 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 48 Months | 5.3 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 60 Months | 7.3 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 12 Months | 5.3 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 24 Months | 6.1 units on a scale |
| Sacral Colpopexy | Change From Baseline Functional Activity Scale | 06 Months | 6.2 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 60 Months | -0.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 06 Months | 6.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 48 Months | 2.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 12 Months | 6.1 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 24 Months | 5.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Functional Activity Scale | 36 Months | 4.9 units on a scale |
Change From Baseline PFDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline PFDI Score | 54 Months | -109.9 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 36 Months | -78.1 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 24 Months | -79.8 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 48 Months | -75.8 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 42 Months | -102.4 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 06 Months | -75.8 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 18 Months | -111.7 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 60 Months | -68.7 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 30 Months | -106.7 units on a scale |
| Native Tissue | Change From Baseline PFDI Score | 12 Months | -79.7 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 42 Months | -114.6 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 12 Months | -85.6 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 18 Months | -111.8 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 24 Months | -84.9 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 30 Months | -112 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 36 Months | -83.9 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 48 Months | -78.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 54 Months | -109.5 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 60 Months | -84.1 units on a scale |
| Sacral Colpopexy | Change From Baseline PFDI Score | 06 Months | -80.2 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 18 Months | -109 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 54 Months | -107 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 24 Months | -79.9 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 42 Months | -103.2 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 60 Months | -67.5 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 06 Months | -79.6 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 36 Months | -79.7 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 12 Months | -79.4 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 48 Months | -73.9 units on a scale |
| Transvaginal Mesh | Change From Baseline PFDI Score | 30 Months | -103.8 units on a scale |
Change From Baseline PFIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline PFIQ Score | 06 Months | -43.9 units on a scale |
| Native Tissue | Change From Baseline PFIQ Score | 24 Months | -41.1 units on a scale |
| Native Tissue | Change From Baseline PFIQ Score | 36 Months | -46.2 units on a scale |
| Native Tissue | Change From Baseline PFIQ Score | 12 Months | -45.8 units on a scale |
| Native Tissue | Change From Baseline PFIQ Score | 48 Months | -39.2 units on a scale |
| Native Tissue | Change From Baseline PFIQ Score | 60 Months | -32.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 60 Months | -46.9 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 12 Months | -46.9 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 48 Months | -42.5 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 06 Months | -46.6 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 24 Months | -46.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PFIQ Score | 36 Months | -45.9 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 24 Months | -45.4 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 48 Months | -32.2 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 60 Months | -21.8 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 06 Months | -47 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 12 Months | -46.8 units on a scale |
| Transvaginal Mesh | Change From Baseline PFIQ Score | 36 Months | -40.3 units on a scale |
Change From Baseline PISQ-IR Sexually Active Average Score
The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. The PISQ-IR Sexually Active-Average Score (SA-AVG) ranges from 0 to 5 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 6, 12, 18, 24, and 36 months and the score at baseline.
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 60 Months | 0.2 units on a scale |
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 36 Months | 0.4 units on a scale |
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 48 Months | 0.3 units on a scale |
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 06 Months | 0.4 units on a scale |
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 24 Months | 0.4 units on a scale |
| Native Tissue | Change From Baseline PISQ-IR Sexually Active Average Score | 12 Months | 0.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 36 Months | 0.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 12 Months | 0.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 24 Months | 0.4 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 48 Months | 0.3 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 60 Months | 0.6 units on a scale |
| Sacral Colpopexy | Change From Baseline PISQ-IR Sexually Active Average Score | 06 Months | 0.4 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 24 Months | 0.5 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 06 Months | 0.5 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 60 Months | 0.3 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 36 Months | 0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 12 Months | 0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline PISQ-IR Sexually Active Average Score | 48 Months | 0.4 units on a scale |
Change From Baseline POPDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POPDI Score | 54 Months | -40.9 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 12 Months | -37.3 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 24 Months | -40.1 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 42 Months | -36.8 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 48 Months | -36.6 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 60 Months | -33.6 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 36 Months | -38.1 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 06 Months | -36.3 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 18 Months | -40.9 units on a scale |
| Native Tissue | Change From Baseline POPDI Score | 30 Months | -39.3 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 36 Months | -39.3 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 06 Months | -38 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 60 Months | -42.2 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 12 Months | -39.8 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 48 Months | -38.2 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 18 Months | -44.2 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 54 Months | -46.5 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 24 Months | -40.7 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 42 Months | -45.3 units on a scale |
| Sacral Colpopexy | Change From Baseline POPDI Score | 30 Months | -44.6 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 36 Months | -38.2 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 42 Months | -40.3 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 48 Months | -37.1 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 54 Months | -39.8 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 30 Months | -37.6 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 06 Months | -37.2 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 12 Months | -38.4 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 18 Months | -41.8 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 60 Months | -32.2 units on a scale |
| Transvaginal Mesh | Change From Baseline POPDI Score | 24 Months | -37.8 units on a scale |
Change From Baseline POPIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POPIQ Score | 12 Months | -18.6 units on a scale |
| Native Tissue | Change From Baseline POPIQ Score | 36 Months | -20.9 units on a scale |
| Native Tissue | Change From Baseline POPIQ Score | 48 Months | -17.9 units on a scale |
| Native Tissue | Change From Baseline POPIQ Score | 60 Months | -17.1 units on a scale |
| Native Tissue | Change From Baseline POPIQ Score | 06 Months | -19 units on a scale |
| Native Tissue | Change From Baseline POPIQ Score | 24 Months | -18.3 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 06 Months | -19 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 12 Months | -19.5 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 24 Months | -20 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 36 Months | -18.8 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 48 Months | -17.3 units on a scale |
| Sacral Colpopexy | Change From Baseline POPIQ Score | 60 Months | -22.3 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 36 Months | -17.9 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 60 Months | -10.9 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 48 Months | -17 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 12 Months | -18.2 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 24 Months | -18.4 units on a scale |
| Transvaginal Mesh | Change From Baseline POPIQ Score | 06 Months | -19.1 units on a scale |
Change From Baseline POP-Q Ba Measurement
POPQ Point Ba represents the most distal (i.e. most dependent) position of any part of the upper anterior vaginal wall (between the vaginal cuff or anterior vaginal fornix and Point Aa). Point Ba coincides with Point Aa (-3 cm) in a woman who has no anterior POP. In a woman with severe POP, Ba coincides with Point C.
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 06 Months | -3.9 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 12 Months | -3.7 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 18 Months | -3.7 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 24 Months | -3.8 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 30 Months | -3.6 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 36 Months | -3.5 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 42 Months | -3.7 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 48 Months | -3.7 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 54 Months | -3.5 cm |
| Native Tissue | Change From Baseline POP-Q Ba Measurement | 60 Months | -3.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 54 Months | -4.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 30 Months | -4.6 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 60 Months | -4.3 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 42 Months | -4.4 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 48 Months | -4.6 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 06 Months | -4.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 12 Months | -4.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 36 Months | -4.6 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 18 Months | -4.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Ba Measurement | 24 Months | -4.3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 18 Months | -4.5 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 24 Months | -4.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 54 Months | -4.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 12 Months | -4.3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 30 Months | -4.2 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 36 Months | -4.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 06 Months | -4.6 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 48 Months | -4.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 42 Months | -4.3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Ba Measurement | 60 Months | -3.6 cm |
Change From Baseline POP-Q Bp Measurement
POP-Q Point Bp represents the most distal position of any part of the upper posterior vaginal wall (between the vaginal cuff or posterior vaginal fornix and Point Ap).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 42 Months | -2.1 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 48 Months | -2.6 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 30 Months | -2.8 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 12 Months | -2.6 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 54 Months | -2.7 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 24 Months | -2.5 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 36 Months | -2.3 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 60 Months | -2.6 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 06 Months | -2.6 cm |
| Native Tissue | Change From Baseline POP-Q Bp Measurement | 18 Months | -2.4 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 06 Months | -2.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 18 Months | -2.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 12 Months | -2.9 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 24 Months | -2.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 60 Months | -2.3 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 42 Months | -2.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 30 Months | -2.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 48 Months | -2.6 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 54 Months | -2.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q Bp Measurement | 36 Months | -2.5 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 60 Months | -3.1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 30 Months | -2.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 36 Months | -2.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 42 Months | -3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 48 Months | -3.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 54 Months | -3.1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 12 Months | -3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 18 Months | -3.1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 24 Months | -2.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q Bp Measurement | 06 Months | -3.2 cm |
Change From Baseline POP-Q C Measurement
POP-Q Point C is measured in cm relative to the hymen with negative values being proximal to the hymen and positive values distal to the hymen. Point C represents either the most distal edge of the cervix or the leading edge of the vaginal cuff after total hysterectomy.
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POP-Q C Measurement | 60 Months | -5.2 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 06 Months | -5.1 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 54 Months | -4.5 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 48 Months | -4.5 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 42 Months | -4.5 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 18 Months | -4.9 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 12 Months | -5.1 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 36 Months | -4.6 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 24 Months | -5 cm |
| Native Tissue | Change From Baseline POP-Q C Measurement | 30 Months | -4.7 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 60 Months | -6.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 12 Months | -6.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 18 Months | -6.8 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 30 Months | -7.1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 36 Months | -7.1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 42 Months | -7 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 48 Months | -6.4 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 24 Months | -6.5 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 54 Months | -6.6 cm |
| Sacral Colpopexy | Change From Baseline POP-Q C Measurement | 06 Months | -6.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 60 Months | -5.5 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 30 Months | -5.4 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 24 Months | -5.7 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 54 Months | -5.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 18 Months | -5.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 12 Months | -5.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 42 Months | -5.6 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 36 Months | -5.7 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 06 Months | -6.1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q C Measurement | 48 Months | -6.1 cm |
Change From Baseline POP-Q TVL Measurement
POP-Q Total Vaginal Length (TVL) is measured in cm. It is the length of the vagina from posterior fornix to the hymen when Point C or D is reduced to its full normal position.
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 06 Months | -0.9 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 12 Months | -1 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 18 Months | -1.1 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 24 Months | -0.9 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 36 Months | -0.9 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 42 Months | -1 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 48 Months | -1.1 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 60 Months | -0.8 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 30 Months | -1.2 cm |
| Native Tissue | Change From Baseline POP-Q TVL Measurement | 54 Months | -1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 24 Months | 0 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 54 Months | -0.1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 36 Months | 0.2 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 30 Months | 0.2 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 42 Months | -0.1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 48 Months | 0 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 06 Months | 0.1 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 12 Months | 0 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 18 Months | 0 cm |
| Sacral Colpopexy | Change From Baseline POP-Q TVL Measurement | 60 Months | -0.3 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 48 Months | -0.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 24 Months | -0.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 60 Months | -0.8 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 06 Months | -0.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 36 Months | -1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 54 Months | -0.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 18 Months | -0.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 42 Months | -1.1 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 30 Months | -0.9 cm |
| Transvaginal Mesh | Change From Baseline POP-Q TVL Measurement | 12 Months | -0.8 cm |
Change From Baseline Surgical Pain Scale Exercise Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 12 Months | -0.8 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 36 Months | -1.1 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 48 Months | -1.3 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 60 Months | -0.6 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 06 Months | -0.6 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Exercise Score | 24 Months | -1.3 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 48 Months | -0.7 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 12 Months | -1.4 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 60 Months | -2.9 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 06 Months | -1.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 36 Months | -1.2 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Exercise Score | 24 Months | -0.4 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 36 Months | -1.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 48 Months | -1.4 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 24 Months | -1.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 06 Months | -1.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 12 Months | -1.3 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Exercise Score | 60 Months | 0.4 units on a scale |
Change From Baseline Surgical Pain Scale Normal Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 36 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 60 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 48 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 06 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 12 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Normal Score | 24 Months | -0.6 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 12 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 24 Months | -0.8 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 36 Months | -0.7 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 06 Months | -0.7 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 60 Months | -1 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Normal Score | 48 Months | -0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 60 Months | 0.5 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 48 Months | -0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 06 Months | -0.9 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 12 Months | -1 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 36 Months | -0.5 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Normal Score | 24 Months | -1 units on a scale |
Change From Baseline Surgical Pain Scale Rest Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 24 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 12 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 60 Months | -0.7 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 06 Months | -0.6 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 36 Months | -0.5 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Rest Score | 48 Months | -0.9 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 36 Months | -0.6 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 24 Months | -0.4 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 48 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 60 Months | -1.1 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 06 Months | -0.5 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Rest Score | 12 Months | -0.4 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 06 Months | -0.7 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 48 Months | -0.2 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 12 Months | -0.8 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 24 Months | -0.6 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 60 Months | 0.2 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Rest Score | 36 Months | -0.2 units on a scale |
Change From Baseline Surgical Pain Scale Worst Score
The Surgical Pain Scale measuring the post-surgical pain experienced by a subject is composed of 4 questions: Pain at Rest (range 0-10), Pain with Normal Activities (range 0-10), Pain with Exercise (range 0-10), and Intensity of Worst Pain (range 0-10). Lower scores indicate better less pain for the Rest subscale, Normal subscale, Exercise Subscale, and Worst Subscale. Change = (Month \[6, 12, 18, 24, and 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 36 Months | -0.4 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 60 Months | -0.6 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 48 Months | -0.3 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 06 Months | -0.7 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 12 Months | -0.8 units on a scale |
| Native Tissue | Change From Baseline Surgical Pain Scale Worst Score | 24 Months | -0.6 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 60 Months | -1.7 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 36 Months | -1.1 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 24 Months | -1.2 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 06 Months | -1.1 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 48 Months | -1 units on a scale |
| Sacral Colpopexy | Change From Baseline Surgical Pain Scale Worst Score | 12 Months | -0.9 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 60 Months | 0.8 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 12 Months | -1.1 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 48 Months | -0.2 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 06 Months | -0.9 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 24 Months | -1 units on a scale |
| Transvaginal Mesh | Change From Baseline Surgical Pain Scale Worst Score | 36 Months | -0.4 units on a scale |
Change From Baseline UDI Score
The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1. Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2. Colorectal Anal Distress Inventory (range: 0-100), and 3. Urinary Distress Inventory (range: 0-100). The range of responses for all questions is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Subscale scores are calculated by multiplying the mean value of all questions answered by 25 for the subscale. The range of score for each subscale is: 0-100 with 0 (least distress) to 100 (most distress). The PFDI is calculated as the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFDI scale, POPDI subscale, CRADI subscale, and UDI subscale. Change from baseline = (Month \[12, 24, 36\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline UDI Score | 48 Months | -26.9 units on a scale |
| Native Tissue | Change From Baseline UDI Score | 60 Months | -27.3 units on a scale |
| Native Tissue | Change From Baseline UDI Score | 36 Months | -28 units on a scale |
| Native Tissue | Change From Baseline UDI Score | 12 Months | -29.5 units on a scale |
| Native Tissue | Change From Baseline UDI Score | 06 Months | -27.3 units on a scale |
| Native Tissue | Change From Baseline UDI Score | 24 Months | -26.8 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 36 Months | -30.2 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 60 Months | -31.4 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 24 Months | -29.5 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 12 Months | -31.2 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 48 Months | -27.9 units on a scale |
| Sacral Colpopexy | Change From Baseline UDI Score | 06 Months | -29.3 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 60 Months | -22.2 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 12 Months | -26.9 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 36 Months | -28 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 48 Months | -24.1 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 06 Months | -28.2 units on a scale |
| Transvaginal Mesh | Change From Baseline UDI Score | 24 Months | -28 units on a scale |
Change From Baseline UIQ Score
The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of an overall score (range 0-300), 3 subscales (7 questions each): the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on all questions is 0-3 with (0) Not at all ... (3), Quite a bit. Subscale scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of scores for each subscale is: 0-100 with 0 (least negative impact) to 100 (most negative impact). The PFIQ is the sum of the three subscales. Lower scores indicate better function / fewer symptoms for the PFIQ score, UIQ score, POPIQ score, and CRAIQ score. Change = (Week \[12, 24\] Score - Baseline Score).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Native Tissue | Change From Baseline UIQ Score | 12 Months | -17 units on a scale |
| Native Tissue | Change From Baseline UIQ Score | 60 Months | -11.5 units on a scale |
| Native Tissue | Change From Baseline UIQ Score | 06 Months | -15 units on a scale |
| Native Tissue | Change From Baseline UIQ Score | 48 Months | -16.3 units on a scale |
| Native Tissue | Change From Baseline UIQ Score | 36 Months | -17.6 units on a scale |
| Native Tissue | Change From Baseline UIQ Score | 24 Months | -15.7 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 60 Months | -17.8 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 06 Months | -18.7 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 12 Months | -18.3 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 24 Months | -17 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 48 Months | -15.9 units on a scale |
| Sacral Colpopexy | Change From Baseline UIQ Score | 36 Months | -17.7 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 12 Months | -18.5 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 06 Months | -18.9 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 60 Months | -8.4 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 48 Months | -11 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 36 Months | -16.3 units on a scale |
| Transvaginal Mesh | Change From Baseline UIQ Score | 24 Months | -17.8 units on a scale |
Number of Participants With PGI-I Reported Improvement
The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).
Time frame: 6 months through 60 Months
Population: An modified intent-to-treat (ITT) analysis which included all eligible participants who were randomized, received the randomized procedure, and who provided outcome data after baseline was performed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 06 Months | No improvement | 16 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 12 Months | No improvement | 9 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 24 Months | Improvement | 87 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 24 Months | No improvement | 10 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 36 Months | Improvement | 79 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 36 Months | No improvement | 12 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 48 Months | Improvement | 58 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 48 Months | No improvement | 15 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 60 Months | Improvement | 33 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 60 Months | No improvement | 8 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 06 Months | Improvement | 96 Participants |
| Native Tissue | Number of Participants With PGI-I Reported Improvement | 12 Months | Improvement | 101 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 60 Months | Improvement | 33 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 36 Months | Improvement | 88 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 06 Months | Improvement | 108 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 36 Months | No improvement | 5 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 60 Months | No improvement | 4 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 48 Months | Improvement | 68 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 48 Months | No improvement | 4 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 06 Months | No improvement | 6 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 12 Months | Improvement | 100 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 12 Months | No improvement | 8 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 24 Months | Improvement | 90 Participants |
| Sacral Colpopexy | Number of Participants With PGI-I Reported Improvement | 24 Months | No improvement | 5 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 24 Months | Improvement | 97 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 24 Months | No improvement | 7 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 60 Months | Improvement | 34 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 12 Months | No improvement | 8 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 36 Months | Improvement | 84 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 06 Months | No improvement | 11 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 06 Months | Improvement | 98 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 36 Months | No improvement | 5 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 12 Months | Improvement | 96 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 48 Months | No improvement | 6 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 48 Months | Improvement | 67 Participants |
| Transvaginal Mesh | Number of Participants With PGI-I Reported Improvement | 60 Months | No improvement | 3 Participants |